Genotype 2, 3, 5 or 6 infection. 
Decompensated cirrhosis defined by the presence of actual or previous history of clinical decompensation including ascites, hepatic encephalopathy, variceal bleeding or spontaneous bacterial peritonitis, or a Child-Pugh B or C. 
Hepatocellular carcinoma after liver transplantation. 
Total bilirubin > 3 mg/dL. 
Immunosuppression with cyclosporine or an mTOR inhibitor (everolimus or sirolimus). 
Severe extrahepatic diseases: cardiovascular, respiratory, cerebrovascular and poorly controlled diabetes. 
Platelets < 75 x 109 cells/L. 
Neutrophil count < 0.5 x 109 cells/L. 
Hemoglobin < 9 g/dL. 
Albumin < 3g/dL. 
HIV infection. 
Hepatitis B infection. 
Active intake of toxic amounts of alcohol or recreational drugs. 
Females who are pregnant, become to be pregnant or breastfeeding or males whose partners are pregnant, become to be pregnant or breastfeeding. 
Intake of disallowed medications including(but not limited to): 
1. Antibiotics: clarithromycin, erythromycin, telithromycin, nafcillin, rifampin 
2. Antifungals: itraconazole, ketoconazole, voriconazole 
3. Antihypertensives: nifedipine 
4. Anticonvulsants: carbamazepine, phenytoin, phenobarbital 
5. Bosentan 
6. Modafinil 
7. St.Jonh's Wort 
8. Immunosuppressants: cyclosporin, everolimus, sirolimus 
9. Diabetes agents: glibenclamide, glyburide 
10. Lipid lowering agents: gemfibrozil 
11. Eltrombopag 
12. Lapatinib 
13. HIV medications: efavirenz, etravirine, all ritonavir boosted and unboosted HIV protease inhibitors 
14. Statins: simvastatin, fluvastatin, rosuvastatin at doses greater than 10 mg/d, atorvastatin at doses greater than 10 mg/d.       
    

NCT02890719_exc_T1
Measurement
Genotype
NCT02890719_exc_T2
Value
2, 3, 5 or 6
NCT02890719_exc_T3
Condition
infection
NCT02890719_exc_T18
Condition
cirrhosis
NCT02890719_exc_T19
Qualifier
Decompensated
NCT02890719_exc_T20
Condition
clinical decompensation
NCT02890719_exc_T22
Condition
ascites
NCT02890719_exc_T23
Condition
hepatic encephalopathy
NCT02890719_exc_T24
Condition
variceal bleeding
NCT02890719_exc_T25
Condition
spontaneous bacterial peritonitis
NCT02890719_exc_T26
Measurement
Child-Pugh
NCT02890719_exc_T27
Value
B or C
NCT02890719_exc_T28
Scope
ascites, hepatic encephalopathy, variceal bleeding or spontaneous bacterial peritonitis, or a Child-Pugh B or C
NCT02890719_exc_T29
Temporal
actual
NCT02890719_exc_T30
Temporal
previous
NCT02890719_exc_T31
Scope
actual or previous
NCT02890719_exc_T32
Condition
Hepatocellular carcinoma
NCT02890719_exc_T33
Procedure
liver transplantation
NCT02890719_exc_T35
Reference_point
liver transplantation
NCT02890719_exc_T36
Temporal
after liver transplantation
NCT02890719_exc_T37
Measurement
Total bilirubin
NCT02890719_exc_T38
Value
> 3 mg/dL
NCT02890719_exc_T39
Procedure
Immunosuppression
NCT02890719_exc_T40
Drug
cyclosporine
NCT02890719_exc_T41
Drug
mTOR inhibitor
NCT02890719_exc_T42
Drug
everolimus
NCT02890719_exc_T43
Drug
sirolimus
NCT02890719_exc_T44
Scope
everolimus or sirolimus
NCT02890719_exc_T45
Scope
cyclosporine or an mTOR inhibitor (everolimus or sirolimus)
NCT02890719_exc_T46
Condition
extrahepatic diseases
NCT02890719_exc_T48
Qualifier
Severe
NCT02890719_exc_T51
Condition
cardiovascular
NCT02890719_exc_T52
Condition
respiratory
NCT02890719_exc_T53
Condition
cerebrovascular
NCT02890719_exc_T54
Condition
diabetes
NCT02890719_exc_T55
Qualifier
poorly controlled
NCT02890719_exc_T57
Scope
cardiovascular, respiratory, cerebrovascular and poorly controlled diabetes
NCT02890719_exc_T58
Measurement
Platelets
NCT02890719_exc_T59
Value
< 75 x 109 cells/L
NCT02890719_exc_T60
Measurement
Neutrophil count
NCT02890719_exc_T61
Value
< 0.5 x 109 cells/L
NCT02890719_exc_T62
Measurement
Hemoglobin
NCT02890719_exc_T63
Value
< 9 g/dL
NCT02890719_exc_T64
Measurement
Albumin
NCT02890719_exc_T65
Value
< 3g/dL
NCT02890719_exc_T66
Condition
HIV infection
NCT02890719_exc_T67
Condition
Hepatitis B infection
NCT02890719_exc_T68
Condition
alcohol
NCT02890719_exc_T69
Multiplier
toxic amounts
NCT02890719_exc_T71
Condition
recreational drugs
NCT02890719_exc_T72
Temporal
Active intake
NCT02890719_exc_T73
Condition
pregnant
NCT02890719_exc_T74
Person
Females
NCT02890719_exc_T75
Observation
become
NCT02890719_exc_T76
Condition
pregnant
NCT02890719_exc_T77
Observation
breastfeeding
NCT02890719_exc_T80
Person
males
NCT02890719_exc_T81
Scope
males whose partners are pregnant, become to be pregnant or breastfeeding
NCT02890719_exc_T82
Scope
Females who are pregnant, become to be pregnant or breastfeeding
NCT02890719_exc_T83
Drug
disallowed medications
NCT02890719_exc_T86
Drug
clarithromycin
NCT02890719_exc_T87
Drug
erythromycin
NCT02890719_exc_T88
Drug
telithromycin
NCT02890719_exc_T89
Drug
nafcillin
NCT02890719_exc_T90
Drug
rifampin
NCT02890719_exc_T91
Drug
itraconazole
NCT02890719_exc_T92
Drug
ketoconazole
NCT02890719_exc_T93
Drug
voriconazole
NCT02890719_exc_T94
Drug
nifedipine
NCT02890719_exc_T95
Drug
carbamazepine
NCT02890719_exc_T96
Drug
phenytoin
NCT02890719_exc_T97
Drug
phenobarbital
NCT02890719_exc_T98
Drug
Bosentan
NCT02890719_exc_T99
Drug
Modafinil
NCT02890719_exc_T100
Drug
St.Jonh's Wort
NCT02890719_exc_T101
Drug
cyclosporin
NCT02890719_exc_T102
Drug
everolimus
NCT02890719_exc_T103
Drug
sirolimus
NCT02890719_exc_T104
Drug
glibenclamide
NCT02890719_exc_T105
Drug
glyburide
NCT02890719_exc_T106
Drug
gemfibrozil
NCT02890719_exc_T107
Drug
Eltrombopag
NCT02890719_exc_T108
Drug
Lapatinib
NCT02890719_exc_T109
Multiplier
doses greater than 10 mg/d
NCT02890719_exc_T110
Drug
HIV protease inhibitors
NCT02890719_exc_T111
Drug
ritonavir
NCT02890719_exc_T112
Drug
etravirine
NCT02890719_exc_T113
Qualifier
ritonavir unboosted
NCT02890719_exc_T114
Qualifier
ritonavir boosted
NCT02890719_exc_T116
Scope
ritonavir boosted and unboosted
NCT02890719_exc_T117
Drug
efavirenz
NCT02890719_exc_T118
Drug
simvastatin
NCT02890719_exc_T119
Drug
fluvastatin
NCT02890719_exc_T120
Drug
rosuvastatin
NCT02890719_exc_T121
Drug
atorvastatin
NCT02890719_exc_T122
Multiplier
doses greater than 10 mg/d